nach oben

Erschienen in:

22.07.2021 | Review Article

Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review

verfasst von: Martin Schmitt, Yvan Pin, MD, MSc, Carole Pflumio, MD, MSc, Carole Mathelin, MD, PhD, Xavier Pivot, MD, PhD, Prof. Georges Noel, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

In breast cancer treatment, radiotherapy is an essential component for locoregional management. Axillary recurrence in patients with invasive breast carcinoma remains an issue. The question of whether breast irradiation may unintentionally include levels I, II, and III, and may decrease the risk of axillary recurrence, remains a topic of discussion.

Patients and methods

A literature search was performed in PubMed and the Cochrane Library to identify articles that have published data regarding dose–volume analysis of axillary levels in breast irradiation. The following MESH terms were used: “breast cancer/lymph nodes” AND “radiotherapy dosage.”

Results

Thirteen articles were identified. The irradiation technique, initial dose prescribed to the breast, delineated volumes, and dose received at axillary levels were heterogeneous. The average dose delivered to axilla levels I, II, and III with three-dimensional conformal radiotherapy using standard fields (ST) ranged between 22 and 43.5 Gy, 3 and 35.6 Gy, and 1.0 and 20.5 Gy, respectively. The average doses delivered to axilla levels I, II, and III with three-dimensional conformal radiotherapy using “high tangential” fields (HT) ranged between 38 and 49.7 Gy, 11 and 47.1 Gy, and 5 and 44.7 Gy, respectively. Finally, the average doses delivered to axilla levels I, II, and III using intensity-modulated radiation therapy (IMRT) were between 14.5 and 42.6 Gy, 3.4 and 35 Gy, and 1.2 and 25.5 Gy, respectively.

Conclusion

Our literature review suggests that the incidental dose delivered to the axilla during whole-breast irradiation is heterogenous and dependent on the irradiation technique used. However, whether this observation can be translated into a therapeutic effect is still a matter of debate.

National Comprehensive Cancer Network (2020) NCCN clinical practice guidelines in oncology. NCCN, Fort Washington

Belkacémi Y, Fourquet A, Cutuli B et al (2011) Radiotherapy for invasive breast cancer: Guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. Crit Rev Oncol Hematol 79:91–102. https://doi.org/10.1016/j.critrevonc.2010.06.002CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784. https://doi.org/10.1016/S0140-6736(11)60993-8CrossRef

Hughes KS, Schnaper LA, Bellon JR et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387. https://doi.org/10.1200/JCO.2012.45.2615CrossRefPubMedPubMedCentral

Poortmans PM, Weltens C, Fortpied C et al (2020) Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30472-1CrossRefPubMed

Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307–316. https://doi.org/10.1056/NEJMoa1415340CrossRefPubMedPubMedCentral

Thorsen LBJ, Offersen BV, Danø H et al (2016) DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol 34:314–320. https://doi.org/10.1200/JCO.2015.63.6456CrossRefPubMed

Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998. https://doi.org/10.1056/NEJMoa1209825CrossRefPubMed

Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305. https://doi.org/10.1016/S1470-2045(13)70035-4CrossRefPubMedPubMedCentral

10.

Solá M, Alberro JA, Fraile M et al (2013) Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 20:120–127. https://doi.org/10.1245/s10434-012-2569-yCrossRefPubMed

11.

Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318:918–926. https://doi.org/10.1001/jama.2017.11470CrossRefPubMedPubMedCentral

12.

Donker M, Slaets L, van Tienhoven G, Rutgers EJT (2015) Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial. Ned Tijdschr Geneeskd 159:A9302PubMed

13.

Latosinsky S, Berrang TS, Cutter CS et al (2012) CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 55:66–69. https://doi.org/10.1503/cjs.036011CrossRefPubMedPubMedCentral

14.

Meattini I, De Santis MC, De Rose F et al (2020) Local treatment of the Axilla in early breast cancer: so many questions, still few answers. Clin Oncol 32:e37–e38. https://doi.org/10.1016/j.clon.2019.08.001CrossRef

15.

Jagsi R, Chadha M, Moni J et al (2014) Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol 32:3600–3606. https://doi.org/10.1200/JCO.2014.56.5838CrossRefPubMedPubMedCentral

16.

Haffty BG, Hunt KK, Harris JR, Buchholz TA (2011) Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol 29:4479–4481. https://doi.org/10.1200/JCO.2011.36.1667CrossRefPubMed

17.

Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B‑32 randomised phase 3 trial. Lancet Oncol 11:927–933. https://doi.org/10.1016/S1470-2045(10)70207-2CrossRefPubMedPubMedCentral

18.

van Wely BJ, Smidt ML, de Kievit IM et al (2008) False-negative sentinel lymph node biopsy. Br J Surg 95:1352–1355. https://doi.org/10.1002/bjs.6348CrossRefPubMed

19.

van Wely BJ, Teerenstra S, Schinagl a DX et al (2011) Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg 98:326–333. https://doi.org/10.1002/bjs.7360CrossRefPubMed

20.

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

21.

Jacobson G, Bunda-Randall N, Wen S, Miller M (2017) Axillary lymph node coverage with 3‑dimensional tangential field irradiation and correlation with heart and lung dose. Adv Radiat Oncol 2:630–635. https://doi.org/10.1016/j.adro.2017.07.005CrossRefPubMedPubMedCentral

22.

Belkacemi Y, Bigorie V, Pan Q et al (2014) Breast radiotherapy (RT) using tangential fields (TgF): a prospective evaluation of the dose distribution in the sentinel lymph node (SLN) area as determined intraoperatively by clip placement. Ann Surg Oncol 21:3758–3765. https://doi.org/10.1245/s10434-014-3966-1CrossRefPubMedPubMedCentral

23.

Krasin M, McCall A, King S et al (2000) Evaluation of a standard breast tangent technique: a dose-volume analysis of tangential irradiation using three-dimensional tools. Int J Radiat Oncol 47:327–333. https://doi.org/10.1016/S0360-3016(00)00449-1CrossRef

24.

Aristei C, Chionne F, Marsella AR et al (2001) Evaluation of level I and II axillary nodes included in the standard breast tangential fields and calculation of the administered dose: results of a prospective study. Int J Radiat Oncol 51:69–73. https://doi.org/10.1016/S0360-3016(01)01595-4CrossRef

25.

Orecchia R, Huscher A, Leonardi MC et al (2005) Irradiation with standard tangential breast fields in patients treated with conservative surgery and sentinel node biopsy: using a three-dimensional tool to evaluate the first level coverage of the axillary nodes. Br J Radiol 78:51–54. https://doi.org/10.1259/bjr/29242407CrossRefPubMed

26.

Reed DR, Lindsley SK, Mann GN et al (2005) Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys 61:358–364. https://doi.org/10.1016/j.ijrobp.2004.06.006CrossRefPubMed

27.

Reznik J, Cicchetti MG, Degaspe B, Fitzgerald TJ (2005) Analysis of axillary coverage during tangential radiation therapy to the breast. Int J Radiat Oncol 61:163–168. https://doi.org/10.1016/j.ijrobp.2004.04.065CrossRef

28.

Alço G, Iğdem SI, Ercan T et al (2010) Coverage of axillary lymph nodes with high tangential fields in breast radiotherapy. BJR 83:1072–1076. https://doi.org/10.1259/bjr/25788274CrossRefPubMedPubMedCentral

29.

Borm KJ, Oechsner M, Düsberg M et al (2020) Irradiation of regional lymph node areas in breast cancer—Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother Oncol 142:195–201. https://doi.org/10.1016/j.radonc.2019.08.021CrossRefPubMed

30.

Kataria T, Bisht SS, Gupta D et al (2013) Incidental radiation to axilla in early breast cancer treated with intensity modulated tangents and comparison with conventional and 3D conformal tangents. Breast 22:1125–1129. https://doi.org/10.1016/j.breast.2013.07.054CrossRefPubMed

31.

Zhang L, Yang Z, Chen X et al (2015) Dose coverage of axillary level I–III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. Oncotarget 6:18183–18191CrossRef

32.

Lee J, Kim S‑W, Son SH (2016) Dosimetric evaluation of incidental irradiation to the axilla during whole breast radiotherapy for patients with left-sided early breast cancer in the IMRT era. Medicine 95:e4036. https://doi.org/10.1097/MD.0000000000004036CrossRefPubMedPubMedCentral

33.

Mayinger M, Borm KJ, Dreher C et al (2019) Incidental dose distribution to locoregional lymph nodes of breast cancer patients undergoing adjuvant radiotherapy with tomotherapy – is it time to adjust current contouring guidelines to the radiation technique? Radiat Oncol. https://doi.org/10.1186/s13014-019-1328-7CrossRefPubMedPubMedCentral

34.

De Santis MC, Bonfantini F, Dispinzieri M et al (2016) Axillary coverage by whole breast irradiation in 1 to 2 positive sentinel lymph nodes in breast cancer patients. Tumori Journal 102(4):409–413CrossRef

35.

Li XA, Tai A, Arthur DW et al (2009) Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys 73:944–951. https://doi.org/10.1016/j.ijrobp.2008.10.034CrossRefPubMedPubMedCentral

36.

Weaver DL, Ashikaga T, Krag DN et al (2011) Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412–421. https://doi.org/10.1056/NEJMoa1008108CrossRefPubMedPubMedCentral

37.

Livi L, Meattini I, Marrazzo L et al (2015) Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5‑year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 51:451–463. https://doi.org/10.1016/j.ejca.2014.12.013CrossRefPubMed

38.

Coles CE, Griffin CL, Kirby AM et al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5‑year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390:1048–1060. https://doi.org/10.1016/S0140-6736(17)31145-5CrossRefPubMedPubMedCentral

39.

Vicini FA, Cecchini RS, White JR et al (2019) Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 394:2155–2164. https://doi.org/10.1016/S0140-6736(19)32514-0CrossRefPubMedPubMedCentral

40.

Whelan TJ, Julian JA, Berrang TS et al (2019) External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 394:2165–2172. https://doi.org/10.1016/S0140-6736(19)32515-2CrossRefPubMed

41.

Gentilini O, Botteri E, Leonardi MC et al (2017) Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy. Radiother Oncol 122:37–44. https://doi.org/10.1016/j.radonc.2016.12.021CrossRefPubMed

42.

Galimberti V, Cole BF, Viale G et al (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19:1385–1393. https://doi.org/10.1016/S1470-2045(18)30380-2CrossRefPubMed

43.

Withers HR, Suwinski R (1998) Radiation dose response for subclinical metastases. Semin Radiat Oncol 8:224–228. https://doi.org/10.1016/S1053-4296(98)80048-9CrossRefPubMed

44.

Marks LB (1990) A standard dose of radiation for “microscopic disease” is not appropriate. Cancer 66:2498–2502. https://doi.org/10.1002/1097-0142(19901215)66:12%3C2498::AID-CNCR2820661209%3E3.0.CO;2-XCrossRefPubMed

45.

Hellman S (1997) Stopping metastases at their source. N Engl J Med 337:996–997. https://doi.org/10.1056/NEJM199710023371408CrossRefPubMed

46.

Jatoi I, Benson JR, Kunkler I (2018) Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? NPJ Breast Cancer 4:8. https://doi.org/10.1038/s41523-018-0061-yCrossRefPubMedPubMedCentral

47.

Berg JW (1955) The significance of axillary node levels in the study of breast carcinoma. Cancer 8:776–778CrossRef

48.

Moher D, Liberati A, Tetzlaff J et al The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097CrossRefPubMedPubMedCentral

Titel: Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review
verfasst von: Martin Schmitt
Yvan Pin, MD, MSc
Carole Pflumio, MD, MSc
Carole Mathelin, MD, PhD
Xavier Pivot, MD, PhD
Prof. Georges Noel, MD, PhD
Publikationsdatum: 22.07.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2021
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-021-01808-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review

Abstract

Background and objective

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background and objective

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer: a single-institution retrospective analysis

MicroRNA-29b regulates the radiosensitivity of esophageal squamous cell carcinoma by regulating the BTG2-mediated cell cycle

Inoperable CASTLE of the thyroid gland treated with radical radiotherapy with complete remission

Strahlentherapie mit 24-Gy-Einzeldosis und 3-Fraktionen-SBRT zur Behandlung von oligometastasierten Malignomen?

[F18] FDG-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful?

Motion-compensated FDG PET/CT for oesophageal cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie